Evommune's MRGPRX2 antagonist flunks its second I&I trial this summer

Evommune's Dermira-derived small molecule has failed a Phase 2b test in atopic dermatitis, marking the second mid-stage flop for the experimental drug this summer. The Palo Alto biotech